Lung Cancer

Skip to main content

Lung Cancer

FLAURA Trial: Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Lung Cancer

ALEX Trial: Alectinib versus Crizotinib in Treatment-Naïve Advanced ALK-Positive NSCLC

Lung Cancer, VEGF Inhibitors

Inhibition of VEGFR and EGFR with Apatinib + Gefitinib as First-Line Therapy Increased Progression-Free Survival

Lung Cancer

Patritumab Deruxtecan Shows Promise in Treating Patients with EGFR-Mutated NSCLC

Lung Cancer

Bevacizumab + Osimertinib Did Not Increase Progression-Free Survival versus Osimertinib Alone in Patients with Advanced Adenocarcinoma and EGFR T790M Mutations

Lung Cancer

Lower Dose of Afatinib Shows Promising Clinical Efficacy in Patients with NSCLC and EGFR Mutation

Lung Cancer

ADAURA Trial: Osimertinib in Resected EGFR-Mutated NSCLC

Lung Cancer

Metastatic Non–Small-Cell Lung Cancer

David Spigel, MD

Lung Cancer

Nonmetastatic Non–Small-Cell Lung Cancer

Geoff Oxnard, MD

Lung Cancer

Small-Cell Lung Cancer and Mesothelioma

David Spigel, MD

4
5
6
7
8
9
10

Page 7 of 12
Results 61 - 70 of 116